DUBLIN--(BUSINESS WIRE)--
Research and Markets (http://www.researchandmarkets.com/research/sdvz8n/pharmapoint) has announced the addition of the "PharmaPoint: Epilepsy - Japan Drug Forecast and Market Analysis to 2022" report to their offering.
Epilepsy is a brain disorder characterized by spontaneously occurring and recurrent seizures. The market is heavily driven by the sales of antiepileptic drugs (AEDs) targeted at seizure reduction. The AED market is currently dominated by UCB's Keppra and GlaxoSmithKline's Lamictal. Although both drugs have experienced significant generic erosion, they form the mainstay of epilepsy treatment in the nine markets and will continue to have significant market share during the forecast period. Other key drugs include older generation AEDs such as Pfizer's Dilantin, Abbott's Depakote, and Novartis' Tegretol and Trileptal which still have significant usage due to their longevity in the market. However, the AED dominance landscape will continue to shift towards newer generation drugs particularly following the recent market entry of GlaxoSmithKline's Trobalt/Potiga and Eisai's Fycompa which both offer first-in-class mechanisms of action.
The main driver for growth in this market will be the launch of new AEDs (Vimpat and Banzel), the continued uptake of recent AEDs (Lamictal, Keppra, and Topina [topiramate]), and the lower-than-average rate of generic substitution in Japan compared with other countries. Government regulations on drug approval and pricing, however, limit or delay drug entry and profitability Japan.
Scope
- Overview of Epilepsy including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in Japan including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in Japan from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting Japan Epilesy market.
Reasons to buy
See the original post here:
Research and Markets: PharmaPoint: Epilepsy - Japan Drug Forecast and Market Analysis to 2022